SCHEMBL4676294

SCHEMBL4676294

Cc1ccc(Cc2[nH]ccc2C(=O)C=C(O)C(=O)O)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.37
KMT2A Q03164 2/20 0.34
CTBP2 P56545 1/20 0.34
KDM4E B2RXH2 1/20 0.33
LMNA P02545 4/20 0.32
IGF1R P08069 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ALDH1A1 P00352 4/20 0.30
HTT P42858 3/20 0.30
NPSR1 Q6W5P4 3/20 0.30
HPGD P15428 2/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30
PKM P14618 2/20 0.30
ATM Q13315 2/20 0.30
NLRP1 Q9C000 1/20 0.30
MEN1 O00255 1/20 0.30
NTSR1 P30989 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676292 1.00 SRD5A2 (0.37) SRD5A2KMT2ACTBP2KDM4ELMNA
SCHEMBL4674707 0.87 PLA2G10 (0.36) KMT2ALMNAMEN1CA12CA1
SCHEMBL4674702 0.87 PLA2G10 (0.36) KMT2ALMNAMEN1CA12CA1
SCHEMBL4677277 0.87 KMT2A (0.45) KMT2ALMNASMN1; SMN2HSD17B10ALDH1A1
SCHEMBL4677274 0.87 KMT2A (0.45) KMT2ALMNASMN1; SMN2HSD17B10ALDH1A1
SCHEMBL4673838 0.86 CTBP2 (0.34) KMT2ACTBP2KDM4ELMNASMN1; SMN2
SCHEMBL4671740 0.86 ITGB1 (0.35) ALDH1A1TDP1
SCHEMBL4671742 0.86 ITGB1 (0.35) ALDH1A1TDP1
SCHEMBL4673842 0.86 CTBP2 (0.34) KMT2ACTBP2KDM4ELMNASMN1; SMN2
SCHEMBL4671494 0.86 SAE1 (0.39) CTBP2SMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SRD5A2 371/4885KMT2A 597/4885CTBP2 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.